This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Opalka, D. Articles by Esser, M. T. Search for Related Content PubMed PubMed Citation Articles by Opalka, D. Articles by Esser, M. T.

Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

Virus and Cell Biology, Merck Research Laboratories, Wayne, Pennsylvania 19087-8630,¹ Microbial Vaccines, Merck Research Laboratories, West Point, Pennsylvania 19486²

Received 6 May 2002/ Returned for modification 13 July 2002/ Accepted 3 October 2002

Several different methods have been developed to quantitate neutralizing antibody responses to human papillomaviruses (HPVs), including in vivo neutralization assays, in vitro pseudoneutralization assays, competitive radioimmunoassays (cRIAs), and enzyme-linked immunosorbent assays. However, each of these techniques possesses one or more limitations that preclude testing large numbers of patient sera for use in natural history studies and large vaccine clinical trials. We describe here a new multiplexed assay, by using the Luminex Laboratory MultiAnalyte Profiling (LabMAP3) assay system, that can simultaneously quantitate neutralizing antibodies to human papillomavirus types 6, 11, 16, and 18 in 50 µl of serum. The HPV-Luminex competitive immunoassay measures titers of polyclonal antibodies in serum capable of displacing phycoerythrin-labeled detection monoclonal antibodies binding to conformationally sensitive, neutralizing epitopes on the respective virus-like particles. This competitive Luminex immunoassay was found to be as sensitive, accurate, and precise as the currently used cRIAs. An effective HPV vaccine will most likely require several distinct genotypes to protect against multiple cancer causing papillomaviruses. The HPV-Luminex immunoassay should prove to be a useful tool in simultaneously quantitating antibody immune responses to multiple HPV genotypes for natural history infection studies and for monitoring the efficacy of prospective vaccines.

This article has been cited by other articles:

• Khan, I. H., Mendoza, S., Yee, J., Deane, M., Venkateswaran, K., Zhou, S. S., Barry, P. A., Lerche, N. W., Luciw, P. A. (2006). Simultaneous Detection of Antibodies to Six Nonhuman-Primate Viruses by Multiplex Microbead Immunoassay. CVI 13: 45-52 [Abstract] [Full Text]  
• Dillner, J. (2005). Toward "Serolomics": Papillomavirus Serology Is Taking a Technologic Lead in High-Throughput Multiplexed Antibody Analysis. Clin. Chem. 51: 1768-1769 [Full Text]  
• Waterboer, T., Sehr, P., Michael, K. M., Franceschi, S., Nieland, J. D., Joos, T. O., Templin, M. F., Pawlita, M. (2005). Multiplex Human Papillomavirus Serology Based on In Situ-Purified Glutathione S-Transferase Fusion Proteins. Clin. Chem. 51: 1845-1853 [Abstract] [Full Text]  
• Dias, D., Van Doren, J., Schlottmann, S., Kelly, S., Puchalski, D., Ruiz, W., Boerckel, P., Kessler, J., Antonello, J. M., Green, T., Brown, M., Smith, J., Chirmule, N., Barr, E., Jansen, K. U., Esser, M. T. (2005). Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18. CVI 12: 959-969 [Abstract] [Full Text]  
• Khan, I. H., Kendall, L. V., Ziman, M., Wong, S., Mendoza, S., Fahey, J., Griffey, S. M., Barthold, S. W., Luciw, P. A. (2005). Simultaneous Serodetection of 10 Highly Prevalent Mouse Infectious Pathogens in a Single Reaction by Multiplex Analysis. CVI 12: 513-519 [Abstract] [Full Text]